A Randomised, Controlled Trial to Investigate the Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Bipolar disorders affect approximately 4.5 million people across the European Union (EU) and are associated with high annual healthcare and societal costs. Bipolar disorder I and II represent disorders that cause extreme fluctuation in a person's mood, energy, and ability to function, in which symptoms of (hypo)mania and depression alternate. The depressive episodes of bipolar disorders are often referred to as bipolar depression (BD). In other words: it is a phase/state of the disorder. For many patients with BD, the depressive polarity is often more pervasive and more debilitating than manic states, with estimates that depressed mood accounts for up to two-thirds of the time spent unwell, even with treatment. The burden of not received an effective treatment for BD is high: more severe psychopathology, higher rates of unemployment, more hospitalisations, lower quality of life, lower cognitive functioning, risk of suicide, comorbidities and poorer social and occupational functioning and thus more carer burden. For BD, the treatment guidelines are very heterogeneous, amongst other reasons because the disease is heterogeneous and treatments should be tailored to the patients. There is no clear treatment algorithm and it cannot yet be predicted which treatment will be effective. Especially the place of adjunctive antidepressants is under debate. Usually, for psychiatric disorders (including bipolar disorder), a patient is considered to be treatment-resistant is two medicinal treatments have been tried (in sufficient duration and dosage) without sufficient success. For BD, there is no consensus on when to consider a patient as treatment-resistant, but the most common definition is after one prior treatment failure. This raises the research question whether adjunctive antidepressants to treat BD should be introduced earlier in the treatment. Additionally, The INTENSIFY trial is part of the larger Horizon 2021 project, with the central goal of paving the way for a shift towards a treatment decision-making process tailored for the individual at risk for treatment resistance. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for treatment resistance across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression.

Start Date31 Jan 2025

Sponsor / Collaborator

University Medical Center of Utrecht

[+1]

NCT05603104

/ RecruitingPhase 3IIT

A Randomised, Controlled Trial to Investigate the Effect of an Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Schizophrenia, bipolar and major depressive disorders collectively affect over 10 million people across the EU and are associated with annual healthcare and societal costs in excess of 100 billion Euros. When diagnosed with one of these disorders, patients are prescribed psychotropic medication such as antidepressants, mood stabilisers or antipsychotics. It is unknown whether this first-line treatment will be successful. After this first-line treatment fails, usually a second-line treatment is initiated, and when this is not successful either a third-line treatment is initiated. Third-line treatments are quite successful, especially when compared to second-line treatments. The research question is whether the third-line treatments (early-intensified treatments) would be more efficacious than the current second-line treatments (treatment as usual) for schizophrenia, bipolar and major depressive disorders. If this is indeed the case, this could lead to the prevention of unnecessary trials of ineffective treatments and adaptations of worldwide guidelines as well as a reduction of healthcare and societal costs.

Start Date30 Jan 2025

Sponsor / Collaborator

University Medical Center of Utrecht

[+1]

NCT06546358

/ Not yet recruitingEarly Phase 1IIT

A Pilot, Double-blind, Randomized Trial of Quetiapine Versus Trazadone in Women With Postpartum Depression

Postpartum depression is a serious disorder that affects approximately 17% of women who have recently given birth. Untreated postpartum depression can negatively affect the mother, the infant, and the family. Lack of sleep is common after delivery and can trigger or worsen depression in some women. Trazodone is used for sleeplessness and depression, but it has not been studied for postpartum depression. There is preliminary evidence that quetiapine, another drug used for depression and sleeplessness, may be effective for postpartum depression. We are planning a study to compare the effectiveness and side effects of quetiapine and trazodone in women with postpartum depression. The results of this study will help us carry out larger studies comparing these drugs with a placebo (a sugar pill) in postpartum depression. We expect the results of our study will improve the mental health of mothers and the well-being of their babies and make it easier for healthcare staff to select the right drug for women with postpartum depression.

Start Date01 Sep 2024

Sponsor / Collaborator

Lawson Health Research Institute

100 Clinical Results associated with Quetiapine Fumarate

100 Translational Medicine associated with Quetiapine Fumarate

100 Patents (Medical) associated with Quetiapine Fumarate

6,009

Literatures (Medical) associated with Quetiapine Fumarate

31 Dec 2025·Dialogues in Clinical Neuroscience

Antipsychotic off-label use in the 21st century: An enduring public health concern

Review

Author: Verdoux, Hélène

Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms. Observational studies confirm the persisting high rate of antipsychotic OLU prescription in two out of three youths and 30-60% of adults using antipsychotics. Increasing rates of low-dose quetiapine prescriptions for anxiety or sleep symptoms are paradigmatic of the current public health concern regarding antipsychotic OLU. Such prescriptions receive impetus from industry-funded marketing strategies and prescribers' feeling of innocuousness, with a resulting underestimation of the risk of adverse drug reactions (ADR). However, antipsychotic OLU should be neither trivialised nor demonised since it may be the only therapeutic option in persons with resistant psychiatric disorders or serious ADR with labelled drugs. To reduce the populational impact of antipsychotic OLU, it is necessary to better control the influence of the pharmaceutical industry regarding newly marketed drugs and to better inform prescribers and users about the risks associated with OLU prescribing.

01 Apr 2025·Journal of Affective Disorders

Quetiapine is associated with pancreatitis: A real-world pharmacovigilance study

Article

Author: Frey, Connor

Quetiapine, an atypical antipsychotic widely prescribed for conditions including schizophrenia and bipolar disorder has been associated with a potential risk of pancreatitis. This study aimed to quantify the association between quetiapine use and the occurrence of pancreatitis using data from the FDA Adverse Events Reporting System. Disproportionality analyses were conducted to evaluate the frequency of pancreatitis reports linked to quetiapine compared to other drugs in the FAERS database. The study identified a significant association between quetiapine and pancreatitis, with a proportional reporting ratio of 30.708, χ² of 81,328.63, relative risk ratio of 27.772, and reporting odds ratio of 32.990, indicating that the risk of pancreatitis is approximately 30 times higher in patients taking quetiapine compared to other medications. These findings suggest that quetiapine poses a considerable risk for the development of pancreatitis, particularly in patients with predisposing factors such as hypertriglyceridemia. This study emphasizes the need for physicians to exercise heightened caution when prescribing quetiapine. While this study provides strong evidence of an association, causality cannot be definitively established, highlighting the necessity for further research to explore the underlying mechanisms and to develop strategies to mitigate this risk.

01 Mar 2025·Sleep Medicine

Trends in anti-insomnia medication utilization among pediatric patients in nine cities in China: A real-world study (2016–2023)

Article

Author: Jiang, Hailun ; Liu, Maochang ; Li, Ziheng ; Xing, Lipeng

OBJECTIVETo investigate prescription patterns of insomnia medications among Chinese children, assess the current status of drug treatment, and offer data to support the guidance of clinical prescribing practices.METHODSThis study analyzed pediatric prescriptions for insomnia medications from the China Hospital Prescription Analysis Cooperation Project database across nine cities between 2016 and 2023. The analysis focused on demographic characteristics, prescription trends, and frequency of medication use among pediatric insomnia patients. Patterns of combination therapy were also examined.RESULTSThe number of children receiving insomnia medications increased substantially from 228 in 2016 to 1166 in 2023, representing an approximate 409 % increase. A growing proportion of patients were aged 12-14 years, with female patients outnumbering males by a ratio of 1.50: 1. There was an increased representation of patients from psychiatry and neurology departments. Regarding medication choices, benzodiazepines (BZDs) remained the most commonly prescribed class, though their use showed a declining trend. Similarly, non-benzodiazepine receptor agonists (nBZRAs) demonstrated a downward trend (P > 0.05), while antidepressant prescriptions significantly increased (P < 0.05). The most commonly prescribed medications within each class were alprazolam, zolpidem, trazodone, sertraline, and quetiapine. A significant proportion of patients (37.25 %) received combination therapy, with benzodiazepine receptor agonists (BZRAs) plus antidepressants being the most common combination.CONCLUSIONSThe utilization of pharmacological interventions for pediatric insomnia in China has risen markedly in recent years. Despite growing concerns about adverse effects, BZDs continue to be the primary therapeutic choice. The increasing prevalence of combination therapy suggests a trend toward more individualized treatment approaches. These findings underscore the importance of careful monitoring and rational prescribing practices in pediatric insomnia management.

News (Medical) associated with Quetiapine Fumarate

03 Sep 2024

·www.echemi.com

After Trials on 703 Patients, Fruquintinib's Application is Rejected, OS Data Proves to Be a Roadblock!

On August 30, HUTCHMED officially announced that it had voluntarily withdrawn its marketing application for fuquinitinib for second-line gastric cancer. This decision was made on the basis that, after in-depth communication with the Center for Drug Evaluation (CDE) of the State Drug Administration and members of its external expert committee, the Company realized that the information submitted so far is not sufficient to meet the approval requirements of the marketing application for the new indication, and therefore further research and data support are needed. Industry observers say this is not surprising. The marketing application for the new indication for fuquintinib was based on data from FRUTIGA's Phase III study, in which only progression-free survival (PFS) achieved the desired effect, while overall survival (OS) improved but was not statistically significant among the two primary endpoints. This shows that CDE is gradually integrating with FDA and paying increasing attention to OS, a key standard. It is well known that the central goal of demonstrating the efficacy of oncology drugs in development is to extend overall survival (OS) of patients. Although multiple alternative endpoints, including PFS, have been used in the past to help bring numerous oncology drugs to market for a variety of reasons, alternative endpoints cannot replace OS as the gold standard. In the past two years, with the tightening of FDA review standards, those drugs that have greater side effects and fail to meet the OS gold standard have been gradually withdrawn from the market, and the approval of new drugs has become more stringent. The current withdrawal of Fuquinitinib appears to signal a new move by domestic regulators, a change that could have far-reaching implications for all oncology drugs. Previously, Fuquinitinib was seen as a potentially effective treatment option for patients with stomach cancer. Gastric cancer is the fifth most common cancer in the world, with a high incidence in China and a large patient population. With the continuous progress of precision medicine, PD-1 combined chemotherapy has become a new standard of first-line treatment for advanced gastric cancer. However, both nationally and globally, the treatment options available for patients with second-line and above treatment options remain limited. The world's major pharmaceutical companies have invested a lot of research resources in this field, promoting a variety of drugs, including PD-1, ADC, VEGFR inhibitors, etc., to enter clinical trials. VEGFR inhibitors play a key role in inhibiting tumor angiogenesis, and previous studies have shown that there are often high levels of VEGF expression in gastric cancer tissues, which is associated with advanced stages of the disease and poor prognosis. Lilly's VEGFR2 monoclonal antibody Ramoxiumab combined with paclitaxel has become the standard second-line chemotherapy regimen for advanced gastric cancer (AGC). Fuquinitinib has shown promising potential as a highly selective oral inhibitor of VEGFR-1, 2, and 3 in Phase III studies. In the FRUTIGA Phase III study, Fuquinitinib combined with paclitaxel was used as a second-line treatment in 703 patients with advanced gastric or gastroesophageal junction adenocarcinoma. The results showed that the median progression-free survival (PFS) was 5.6 months in patients treated with fuquintinib plus paclitaxel, compared with 2.7 months in patients treated with paclitaxel alone (HR=0.569, p < 0.0001). Overall survival (OS) also improved, at 9.6 versus 8.4 months, although the difference was not statistically significant. In terms of safety, the safety characteristics of fuquinitinib were consistent with previous studies, and no new safety problems were found. Clearly, the FRUTIGA Phase III study confirmed that the combination of fuquintinib and paclitaxel significantly prolonged PFS in patients compared to paclitaxel monotherapy. In addition, the objective response rate (ORR, 42.5% vs. 22.4%), disease control rate (DCR, 77.2% vs. 56.3%) and median duration of response (mDoR, 5.5 months vs. 3.7 months) in the combination treatment group were significantly better than those in the paclitaxel monotherapy group. At the ASCO Congress, HUTCHMED presented further analysis of key subgroups in FRUTIGA's Phase III study, showing that PFS and OS results were consistent with those of the intended treatment population. The combination of fuquinitinib and paclitaxel showed a clear PFS benefit in most subgroups, especially in the enteric subgroup and the lymph node metastasis subgroup, where the benefits of PFS and OS were particularly significant. In clinical design, PFS and OS are used as double primary endpoints, alpha resolution and circulation. Studies are considered positive when at least one endpoint reaches statistical significance. Nevertheless, HUTCHMED believes that despite not meeting the OS endpoint, the available clinical data and findings are sufficient to support the combination of fuquinitinib and paclitaxel as a new treatment option for second-line patients with gastric cancer, and had filed a marketing application last year. However, the CDE rejected the application for fuquitinib. HUTCHMED noted that although the higher and uneven proportion of patients receiving subsequent antitumor therapy (20% higher in the paclitaxel monotherapy group than in the combination group) may have influenced OS results, fuquinitinib combined with paclitaxel demonstrated meaningful clinical benefits and favorable OS trends across a range of models. However, the CDE does not agree with this understanding of the OS results, arguing that the available data are not yet sufficient to support marketing applications for new indications and that further research is needed. In other words, CDE expects to see more and more favorable OS data. The CDE's rigorous scrutiny of OS data is justified because overall survival data is critical for evaluating the clinical effectiveness of cancer treatments, and it directly reflects how long patients survive after receiving treatment. Based on international experience, the FDA has in the past allowed progression-free survival as a primary endpoint to provide a path to accelerated approval for drugs to market. But in the past two years, there has been a marked shift in the FDA's regulatory attitude. A batch of drugs, including ibrutinib, are voluntarily withdrawn from the market or the indication is withdrawn under the guidance of the FDA due to confirmatory clinical data failing to meet expectations, or large side effects, or limited overall survival benefits; For some new drug/new indication applications, the FDA has also begun to review OS data. At the heart of the FDA's change of heart is the fact that while some oncology drugs are marketed with alternative endpoints such as progression-free survival or objective response rates, they ultimately fail to equate these alternative endpoints with the gold standard of OS. As a result, the FDA is increasingly looking to companies to provide reliable OS data to prove that new therapies really help patients live longer. The FDA's change did not come in the form of draft guidance, but was communicated to drug companies through meetings, articles and comments from the agency's top oncologists. The CDE of cefuroxime quetiapine for the "stop", may be the beginning of a new trend. What impact this will have on cancer drug development is worth further observation.

Phase 3Clinical ResultAccelerated ApprovalNDA

02 Aug 2024

·www.echemi.com

Unexpected Setback in Rare Disease Drug Development: Takeaways from Takeda's Phase 3 Trial Failure

Recently, a well-known global takeda pharmaceuticals in its latest financial report revealed a regrettable news, which is developing the rare disease drug Soticlestat on two kinds of rare and refractory epilepsy type - and Lennox - Gastaut Dravet syndrome syndrome (LGS) the key phase III clinical trial, Failed to reach the expected effect of main goal. The results will undoubtedly bring takeda pharmaceuticals of new drug research and development of the road for a certain amount of uncertainty. Soticlestat has shown promising therapeutic potential and safety in early phase II trials, but the results of phase III trials have failed to replicate these positive signs. In SKYLINE test for Dravet syndrome patients, Soticlestat failed to significantly reduce the frequency of seizure epilepsy seizures, although in some secondary efficacy on indicators are still showing a certain clinical significance. In the SKYWAY trial, Soticlestat similarly did not significantly reduce the frequency of major motor drop seizures in patients with LGS. Takeda was undeterred by the results, which did not meet expectations. Company said that their potential indications of Soticlestat Dravet remained cautious optimism, with regulators and plan discussed in the complete clinical data, to determine the next step development strategy. However, Soticlestat accumulated hundreds of millions of dollars of losses in the process of r&d, undoubtedly has brought the financial position of the takeda extra pressure. Despite the challenges, Takeda's overall performance in the first quarter of fiscal 2021 remained strong. In the digestive tract tumor and rare diseases in the field of core product sales continue to maintain strong growth, new drug cefuroxime quetiapine for his excellent performance in the us market also has injected new vitality to the company's financial performance. These positive factors to make the industry for the future of takeda pharmaceuticals revenues and profits return to growth remain optimistic expectations. For the frustrations of takeda pharmaceuticals in the Soticlestat test, we should be more understanding and tolerant attitude to look at. New drug research and development is a challenging process, even if is the industry leader is also hard to avoid failure. Is the key to the company how to draw experience from this setback, with more the spirit of perseverance and innovation to promote the future development plan, in order to bring more treatment options for patients with global.

Phase 3Phase 2Financial StatementClinical Trial FailureNDA

22 Jul 2024

·firstwordpharma.com

J&J seeks monotherapy nod for Spravato in resistant depression

Johnson & Johnson said Monday that it filed an application to the FDA to broaden the label of Spravato (esketamine) nasal spray to include monotherapy in adult patients with treatment-resistant depression (TRD). If approved, that would position Spravato as the first standalone therapy for this challenging subset of depression patients.The NMDA receptor agonist was initially approved in 2019 in the US and Europe to treat TRD in combination with an oral antidepressant, and was later also cleared by the FDA to treat depressive symptoms in adults with acute suicidal ideation or behaviour.The new filing is supported by positive results from the Phase IV TRD4005 study, which showed rapid improvement in depressive symptoms based on the Montgomery-Åsberg Depression Rating Scale (MADRS), seen as early as 24 hours after the first dose and sustained through at least four weeks of treatment. J&J said the safety profile of Spravato monotherapy was consistent with existing clinical data for its use in combination with an oral antidepressant. No new safety signals emerged."Many patients living with challenging-to-treat depression spend far too long cycling through multiple treatments that don't effectively resolve their symptoms," said Bill Martin, J&J's global therapeutic area head for neuroscience. "[We]…look forward to working with the FDA to bring this innovative treatment to patients as a monotherapy option."The new filing builds on Spravato's growing commercial success. In 2023, the drug generated sales of $689 million, marking an 84% increase from the previous year. If approved as monotherapy, the drug could offer a new option for the nearly 30% of 280 million people worldwide living with major depressive disorder who have TRD, which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.Spravato's potential expansion as a monotherapy comes on the heels of positive results from the Phase III ESCAPE-TRD trial, reported in November. That study compared Spravato to quetiapine XR, both in combination with continuing antidepressant therapy, in adults with TRD. Spravato demonstrated superiority in achieving remission after 8 weeks, with just over 27% of recipients reaching remission compared to about 18% in the quetiapine XR arm.

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Quetiapine Fumarate

External Link

KEGG	Wiki	ATC	Drug Bank
D00458	Quetiapine Fumarate	N05AH04	DB01224

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bipolar and Related Disorders	JP	Kyowa Pharmaceutical Industry Co., Ltd.	03 Jul 2017
Bipolar I disorder	US	Intellipharmaceutics International, Inc.	09 May 2017
Bipolar I disorder	US	PharmaDax Inc.	09 May 2017
Bipolar II disorder	US	PharmaDax Inc.	09 May 2017
Depressive Disorder	US	PharmaDax Inc.	09 May 2017
Depressive Disorder	US	Intellipharmaceutics International, Inc.	09 May 2017
Depressive Disorder, Major	US	AstraZeneca UK Ltd.	02 Dec 2009
Bipolar Disorder	US	AstraZeneca Pharmaceuticals LP	26 Sep 1997
Schizophrenia	US	AstraZeneca Pharmaceuticals LP	26 Sep 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar I disorder	Phase 3	US	Endo Operations Ltd.	09 May 2017
Depressive Disorder, Major	Phase 3	US	Endo Operations Ltd.	09 May 2017
Schizophrenia	Phase 1	US	Endo Operations Ltd.	09 May 2017
Schizophrenia	Phase 1	US	Endo Operations Ltd.	09 May 2017
Alzheimer Disease	Discovery	-	AstraZeneca PLC	01 Sep 2002
Obsessive-Compulsive Disorder	Discovery	DE	AstraZeneca PLC	01 Apr 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FRI662 (ENDO2023)	Not Applicable	Hypoglycemia	-	Quetiapine	jxxnbbgqpx(qdyajydvjx) = Severe hypoglycemia from treatment with quetiapine hwhjhgzhsz (juvdugtizb )	Positive	05 Oct 2023
				Glucagon
NCT04338321 (ESCAPE-TRD, CTgov)	Phase 3	Depressive Disorder, Major	676	Esketamine (Esketamine Nasal Spray + Oral Antidepressant (AD))	pwixtdfbkv(iszguketrr) = gzfvbrrsrx mowlobobsp (xxvdxrfbnx, lqnyhsehbf - tflppwcalf) View more	-	15 Feb 2023
				Quetiapine (Quetiapine Extended Release (XR) + Oral AD)	pwixtdfbkv(iszguketrr) = gtivakvtau mowlobobsp (xxvdxrfbnx, secltjkrbo - lpyteccuej) View more
NCT01858948 (CTgov)	Phase 3	Metabolic Syndrome \| Bipolar Disorder	19	Placebo+Quetiapine fumarate	(pmhcgaepyu) = uknabdhlbj wfuhycqhzm (dowgmtwiqn, aghnufrzmc - lgbdnmfdmo) View more	-	25 Nov 2022
MDS2022	Not Applicable	Psychotic Disorders \| Parkinson Disease	-	Pimavanserin	ggwdsynjos(uytupndivp) = qlxhrgloao bajlahpbcp (jdlygjaoza, 49 - 267) View more	Positive	15 Sep 2022
				Other Atypical Antipsychotics	bqqldgiqsy(vhfmbcjwzp) = plmfgzoxmu agvxirtosc (vwsjueqtzd )
NCT03321526 (CTgov)	Phase 2	Depressive Disorder, Major	107	serotonin-norepinephrine reuptake+seltorexant (Seltorexant)	bxqmgmepzf(pysshsskcy) = tbhkrtrgjm rfzjycjmkt (nglavjarac, nydvmkbyhy - bgoitgabse) View more	-	16 Aug 2022
				Quetiapine XR (Quetiapine XR)	bxqmgmepzf(pysshsskcy) = tdaqrlqsqf rfzjycjmkt (nglavjarac, uhymdmyqcj - hjxozxbksd) View more
NCT02845453 (CTgov)	Phase 4	Bipolar Disorder \| Substance Abuse	24	Quetiapine (Quetiapine)	lcvghqqkae(lsnddlvhxc) = pyujrlfynd trqxpigpww (wqqgmxtemd, gkozbzjlru - rtsycwnvzq) View more	-	18 Apr 2022
				Placebo (Placebo)	lcvghqqkae(lsnddlvhxc) = klwfdjupff trqxpigpww (wqqgmxtemd, otpspggszp - nrlrhgeetd) View more
NCT00688818 (Pubmed \| J Clin Psychiatry)	Not Applicable	Depressive Disorder \| Anxiety Disorders Add-on	76	Quetiapine XR	(jyisjetswh) = jrnxibflnc yjbgrioigm (pywmhxyqlf, -7.41 to -0.64) View more	Positive	21 Mar 2022
NCT04164758 (CTgov)	Phase 2	Neuropsychiatric syndrome \| Sedation \| Parkinson Disease	11	Placebo (Placebo)	(nywiruxjua) = kmtvodmqdj skjzzhjquo (uerzemzzgf, jwfiaxxics - hjuduthsmy) View more	-	14 Oct 2021
				Quetiapine (Quetiapine)	(nywiruxjua) = ojzhzezycp skjzzhjquo (uerzemzzgf, oyfwgmihht - odsycxmdqv) View more
NCT03557931 (CTgov)	Phase 2	Cognitive Dysfunction \| Schizophrenia	233	risperidone+aripiprazole+placebo+paliperidone+olanzapine+lurasidone+brexpiprazole+ziprasidone+Quetiapine (Placebo)	tmvwvmfeau(bzsfbwscry) = hsbznznusz maflufablb (gshdwyetwq, ljeforiscy - nzugywcwiw) View more	-	27 Oct 2020
				risperidone+aripiprazole+paliperidone+olanzapine+lurasidone+ASP4345+brexpiprazole+ziprasidone+Quetiapine (ASP4345 150 mg)	tmvwvmfeau(bzsfbwscry) = eirgqxydui maflufablb (gshdwyetwq, ndrbhmmvqr - iyeodxheae) View more
NCT03568500 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	44	Digital Medicine System+Aripiprazole (Aripiprazole)	yhvbyslway(qaagnmzidm) = iuroocvaie erkkeifsts (mgqsxttmbb, dacqjnhgcl - ymwxagxomy) View more	-	16 Jul 2020
				Digital Medicine System+Olanzapine (Olanzapine)	yhvbyslway(qaagnmzidm) = xztvtjosjp erkkeifsts (mgqsxttmbb, uyqudntyzl - azlftymryv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis